Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast

MLF Knuckles, E Levi, J Soung - Journal of Dermatological …, 2019 - Taylor & Francis
Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, was effective in clinical trials in
patients with moderate plaque psoriasis (affected body surface area [BSA] 5% to 10%) …
被引用次数：8 相关文章
[HTML] tandfonline.com

[HTML][HTML] Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast

MLF Knuckles, E Levi, J Soung - Journal of Dermatological …, 2018 - Taylor & Francis
Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, was effective in clinical trials in
patients with moderate plaque psoriasis (affected body surface area [BSA] 5% to 10%) …
[PDF] academia.edu

[PDF][PDF] Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast

MLF Knuckles, E Levi, J Soung - 2018 - academia.edu
Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, was effective in clinical trials in
patients with moderate plaque psoriasis (affected body surface area [BSA] 5% to 10%) …

Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast.

MLF Knuckles, E Levi, J Soung - The Journal of Dermatological …, 2018 - europepmc.org
Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, was effective in clinical trials in
patients with moderate plaque psoriasis (affected body surface area [BSA] 5% to 10%) …

Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast

MLF Knuckles, E Levi, J Soung - The Journal of …, 2019 - pubmed.ncbi.nlm.nih.gov
Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, was effective in clinical trials in
patients with moderate plaque psoriasis (affected body surface area [BSA] 5% to 10%) …